News

The cohort is evaluating the antibody-drug conjugate PADCEV (enfortumab vedotin-ejfv) for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor

The acquisition is for the entire issued share capital of Vernalis (R&D) Limited, for $25M in cash. The closing of this transaction is subject to customary conditions and

The halted trails also include the large-scale, pivotal and multi-country phase 3 ENSEMBLE trial of the company’s Covid-19 vaccine candidate called JNJ-78436735, which is being developed by Janssen

True North met both primary endpoints, demonstrating highly statistically significant and clinically meaningful results for clinical remission compared to placebo at induction at Week 10 (18.4% versus 6.0%;

ASC42 is an in-house developed novel non-steroidal, selective, potent Farnesoid X Receptor (FXR) agonist with best-in-class potential. In two NASH animal models, ASC42 demonstrated significant improvements in liver

The phase 3 PENELOPE-B trial has failed to achieve the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), along with Inova Health System, has sponsored the trial. Fostamatinib, which is sold

NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care

The deal also includes an option that allows supply of up to 200 million additional doses to the EU member states. This agreement was signed after the conclusion